Keywords: zevalin, boosts, pfs, follicular, lymphoma, bayer, schering

Zevalin boosts PFS in follicular lymphoma

Article | 17 December 2007

Bayer Schering Pharma, part of Germany's Bayer group, says that its drug Zevalin ([90Y] ibritumomab tiusetan) significantly improves progression-free survival ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Bayer

Go to company listing

Related Drugs

Ibritumomab Tiuxetan

Zevalin

Aspirin

Bayer

Go to drug listing